Gestational Diabetes Mellitus: collaboration Between Nursing, Pharmacists, and Clinical Pathology in Diagnosis, Management, and Treatment.

Abstract

Background: Gestational diabetes mellitus (GDM) is a metabolic disorder that typically arises in the second and third trimesters of pregnancy, characterized by glucose intolerance. It is increasingly prevalent due to factors such as obesity, sedentary lifestyles, and advanced maternal age. GDM can lead to severe complications such as preeclampsia, macrosomia, and neonatal hyperbilirubinemia. Furthermore, women with GDM are at higher risk of developing type 2 diabetes later in life. Early detection and proper management are critical in preventing both short-term and long-term maternal and fetal complications. However, existing diagnostic criteria and treatment options remain subjects of debate.

Aim: This article explores the collaboration between nursing, pharmacists, and clinical pathology in the diagnosis, management, and treatment of GDM. It aims to highlight how an interdisciplinary approach can improve patient outcomes and identify the need for optimized diagnostic and treatment protocols.

Methods: The article reviews the current literature on GDM, focusing on epidemiology, risk factors, pathogenesis, diagnosis, and treatment. The collaborative roles of nursing, pharmacy, and pathology professionals are discussed, emphasizing how each discipline contributes to GDM care.

Results: Key findings suggest that an integrated care approach improves early detection, better management of blood glucose levels, and a reduction in complications. The role of biomarkers in predicting and diagnosing GDM is highlighted, with specific markers such as leptin and adiponectin showing promise. Additionally, the article discusses various diagnostic methods and the importance of personalized care.

Conclusion: Collaboration among nursing, pharmacists, and clinical pathology is essential for the effective management of GDM. This teamwork ensures timely diagnosis, appropriate treatment, and continuous monitoring, improving both maternal and fetal health outcomes. Further research into biomarkers and new diagnostic criteria is needed to enhance early detection and treatment strategies.